Skin Test Study of BM32

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

September 30, 2011

Conditions
Hypersensitivity
Interventions
BIOLOGICAL

BM32

BM32 will be applied in sterile phosphate buffer solution. Drug will be applied in concentrations of 11,33 and 100 micrograms/ml

Trial Locations (1)

1090

Medical University, Vienna

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Medical University of Vienna

OTHER

lead

Biomay AG

INDUSTRY

NCT01350635 - Skin Test Study of BM32 | Biotech Hunter | Biotech Hunter